



HHS Public Access

Author manuscript

Nutr Today. Author manuscript; available in PMC 2017 July 01.

Published in final edited form as:

Nutr Today. 2016 ; 51(4): 167–174. doi:10.1097/NT.000000000000167.

The Gut Microbiome and Its Role in Obesity

Cindy D. Davis, Ph.D.

Office of Dietary Supplements, National Institutes of Health, 6100 Executive Blvd, Suite 3B01, Bethesda, MD 20892-75173, Phone: 301-496-0168, Fax: 301-480-1845, davisci@mail.nih.gov

Abstract

The human body is host to a vast number of microbes, including bacterial, fungal and protozoal microorganisms, which together constitute our microbiota. Evidence is emerging that the intestinal microbiome is intrinsically linked with overall health, including obesity risk. Obesity and obesity-related metabolic disorders are characterized by specific alterations in the composition and function of the human gut microbiome. Mechanistic studies have indicated that the gastrointestinal microbiota can influence both sides of the energy balance equation; namely, as a factor influencing energy utilization from the diet and as a factor that influences host genes that regulate energy expenditure and storage. Moreover, its composition is not fixed and can be influenced by several dietary components. This fact raises the attractive possibility that manipulating the gut microbiota could facilitate weight loss or prevent obesity in humans. Emerging as possible strategies for obesity prevention and/or treatment are targeting the microbiota, in order to restore or modulate its composition through the consumption of live bacteria (probiotics), nondigestible or limited digestible food constituents such as oligosaccharides (prebiotics), or both (synbiotics), or even fecal transplants.

The human gastrointestinal tract is colonized by large numbers of microorganisms, including bacteria, archaea, viruses, fungi and protozoa, collectively known as the gut microbiota. The human gut microbiota (see Table 1) consists of up to 100 trillion microbes and possesses at least 100 times more genes (the microbiome) than are present in the entire human genome.¹ These microbes serve a number of important functions including: producing additional energy otherwise inaccessible to the host by breaking down soluble fiber; producing vitamins such as biotin, folate and vitamin K; metabolizing xenobiotics such as the inactivation of heterocyclic amines formed in meat during cooking; preventing colonization by pathogens; and assisting in the development of a mature immune system. Currently, the bulk of microbiome research is focused on the gut microbiota since this is where the majority of bacteria are found. However, most data are obtained from analysis of stool samples because these are easily accessible. Comparisons of microbiota from colonic mucosal biopsies and stool samples have shown that there are compositional differences between the mucosa-associated and the luminal (fecal) microbiota and thus stool analysis might not accurately reflect the gastrointestinal tract.² Regardless, microbiome analysis has

The author has no conflicts of interest to report

The author is an employee of the National Institutes of Health

revealed a relationship between nutrition, the gut microbiota and a number of human diseases including obesity.

Call out: The microbiota is all of the organisms in an environment while the microbiome is their collective genome

For the analyses of gut microbiota composition, several different techniques have been utilized. Traditional techniques included the isolation and culturing of microorganisms in different growth media. However, the majority of the bacteria in the colon are anaerobic and cannot be cultured under aerobic conditions, so only about 30% of the gut bacteria can be analyzed this way.³ More recently, culture-independent DNA-based methods have allowed for a more extensive characterization of the gastrointestinal microbiota. DNA-based microbiome studies usually fall into one of two categories.⁴ Targeted studies, which focus on one or a few marker genes, use these markers to identify the composition and diversity of the microbiota. Targeted studies are frequently based on the analysis of 16s ribosomal RNA (16s rRNA), which is a part of the small subunit of the bacterial ribosome. Other studies use a metagenomic approach. Metagenomics refer to the collective study of all genomes within a sample and can be performed by “shotgun sequencing” (Table 1) in which representative gene fragments are sequenced. While metagenomics can provide information about the genetic potential of the microbial community, it only provides information on the encoded functional capacity of the microbiome and not on whether or not specific genes are expressed. In addition, metagenomics provides less detailed information on the specific microorganisms present than targeted studies. Thus a combination of both approaches provides the best information on which microbes are there and what they potentially can do.

The dynamic relationship between obesity and the gut microbiota

The bacteria in our gut not only play an important role in digestion but research indicates that our microbiome could also play a major role in whether or not we become obese.

Animal Studies—Gut microbes play a major role in energy extraction from food through a variety of mechanisms. Many plant polysaccharides and complex carbohydrates cannot be digested by the host; however, the gut microbes can metabolize these to short chain fatty acids (SCFA), such as butyrate, propionate and acetate. Butyrate is used as the primary energy source for colonic epithelial cells, while propionate and acetate are necessary for lipogenesis and gluconeogenesis in the liver.⁵ Differences in SCFA levels have been observed in obese and lean mice. For example, in a genetic model of obesity, *ob/ob* mice have increased butyrate and acetate concentrations in their ceca and less energy, determined by bomb calorimetry, in their feces compared to their lean counterparts.⁵

A link between obesity and the gut microbiota was initially suggested based on studies in germ-free mice. These mice are raised in a sterile environment and have no microorganisms in their gut. Conventionally reared mice have a 40% higher body fat content and 47% higher gonadal fat content than germ-free mice even though they consume less food than their germ-free counterparts.⁶ Furthermore, when the distal gut microbiota from the normal mice was transplanted into the gnotobiotic mice, there was a 60% increase in body fat within 2

weeks without any increase in food consumption or obvious differences in energy expenditure suggesting that the gut microbiota affects phenotypic characteristics related to obesity of the host. Mechanistic studies revealed that the transplanted microbiota not only increased caloric release from dietary plant polysaccharides, but also modulated host genes that affect energy deposition in adipocytes including fasting-induced adipocyte factor (Fiaf).⁶ Fiaf is a circulating lipoprotein lipase inhibitor and its suppression is essential for the microbiota-induced deposition of triglycerides in adipocytes. These findings suggest that the presence of a gut microbial community may affect the amount of energy that is extracted from the diet and thus the adiposity of the host.⁶

Call out: Germ-free mice can eat more and gain less weight than conventional mice

In contrast to mice with a gut microbiota, germ-free animals are protected against the obesity that develops after consumption of a Western-style, high fat, sugar-rich diet.⁷ Their continuously lean phenotype is associated with increased skeletal muscle levels of AMP-activated protein kinase and its downstream targets involved in fatty acid oxidation such as acetyl-CoA carboxylase and carnitine-palmitoyl transferase.⁸ Moreover, germ-free knockout animals lacking Fiaf are not protected from diet-induced obesity because of reduced expression of genes involved in fatty acid oxidation.⁸ These findings suggest that the gut microbiota can influence both sides of the energy balance equation; namely, as a factor that influences energy utilization from the diet and as a factor that affects host genes that regulate how energy is expended and stored.⁸ It is not currently known whether the microbiota has a similar effect on energy utilization and gene expression patterns in humans.

Associations between obesity and changes in microbiota composition such as reduced bacterial diversity and/or altered representation of bacterial genes and metabolic pathways has been observed. Mice that are genetically obese (*ob/ob*) have a higher proportion of intestinal *Firmicutes* and 50% fewer *Bacteroidetes*, and a parallel enrichment of microbial genes involved in polysaccharide degradation than their lean siblings.⁹ When germ-free mice were colonized with either the microbiota from obese (*ob/ob*) or lean (+/+) littermates, the mice given the microbiota from obese mice extracted more calories from their food and had a significantly greater increase in total body fat than in mice colonized with the microbiota from lean mice (mean percent of fat gain, 47% versus 27%; representing a difference of 4 kcal or 2% of total calories consumed).⁵ These data suggest that differences in the efficiency of caloric extraction from food may be determined by the microbiota, further suggesting a microbial component in the pathogenesis of obesity.

Transplantation studies using the gut microbiota from human twins discordant for obesity have shown that germ-free mice inoculated with microbiota from obese or lean human twins take on the microbiota characteristics of the donor.¹⁰ Those receiving the obese microbiota had an increase in adiposity, whereas those receiving the lean microbiota remained lean. Interestingly, co-housing of mice harboring cultured bacteria from an obese twin with mice harboring cultured bacteria from a lean twin prevented the development of increased adiposity in the obese mice.¹⁰ This occurred in tandem with successful colonization of obese

mice intestine with bacteria, particularly *Bacteroidetes* from the lean mice. In contrast, obese microbes did not transmit to lean mice and these mice remained lean¹⁰ which indicated that transmissibility of intestinal microbes and adiposity phenotype were tightly linked and the lean phenotype is dominant.

While rodent models have provided an understanding about the contributions of the gut microbiota to obesity, they are limited by physiological and metabolic differences from humans. Gnotobiotic pig models have been developed and gnotobiotic pigs colonized with human microbiota are a powerful research tool.¹¹

Call out: The use of antibiotics may contribute to the development of obesity

The use of antibiotics may also be contributing to the obesity epidemic.¹² The cecal microbiota from 18-week-old controls and penicillin-treated mice were transferred to 3-week-old germ-free mice to investigate the effects on body composition and metabolism. Mice whose mothers were treated with penicillin before the birth of the pups and throughout the weaning process had a markedly altered body composition in adulthood, with increased total and fat mass, increased hepatic expression of genes involved in adipogenesis, decreased bone mineral content, and increased bone surface area. However, the body composition of adult male mice who had received penicillin after weaning was similar to that of controls.¹² These results suggest that the use of antibiotics during early life can induce lasting effects on the body composition by altering the intestinal microbiota.

One of the most durably effective treatments for severe obesity is gastric bypass surgery. Despite its powerful effect on weight loss, the cost and associated risk of this procedure prevents its application to a larger population of severely obese patients, prompting a search for less invasive treatments. In a study using a mouse model of gastric bypass surgery to characterize changes in the gut microbiota, gastric bypass induced substantial, rapid and sustained changes in the gut microbial communities that were independent of both diet and the weight loss associated with this procedure since mice given a sham procedure and put on a calorie restricted diet had the decreased weight loss but not the change in microbiota.¹³ Moreover, transfer of the surgically altered microbial community to non-operated germ-free mice resulted in weight loss despite higher food intake in the animals that got the microbiota from the gastric bypass animals than in those that received the microbiota from the sham animals. This was associated with alterations in the microbiota composition. These observations demonstrate that specific alterations in the gut microbiota contribute to the beneficial effects of bariatric surgery on energy balance and obesity.

Human Studies

The association between the gut microbiota and obesity has also been observed in humans. In overweight/obese humans, low fecal bacterial diversity is associated with more marked overall adiposity and dyslipidemia, impaired glucose homeostasis and higher low-grade inflammation.¹⁴ Investigators have used genetic sequencing of fecal samples to identify the different strains of bacteria in the gut of 12 obese individuals and compared them with five

lean volunteers.⁹ Obese individuals had more *Firmicutes* and nearly 90% less *Bacteroidetes* than the lean individuals. Furthermore, when obese volunteers consumed a low-fat or low-carbohydrate diet for one year and lost as much as 25% of their body weight, the proportion of *Firmicutes* in their colon dropped and that of the *Bacteroidetes* rose. However, the levels of the two types of bacteria never reached those of the group that was lean in the beginning.⁹ In another study, variations in the fecal microbiota of 12 lean and nine obese individuals during diets that varied in caloric content (2400 kcal/day vs. 3400 kcal/day) showed that an altered nutrient load induced rapid changes in the gut bacterial community.¹⁵ Moreover, the higher caloric intake was associated with a 20% growth of *Firmicutes* and a 20% reduction in *Bacteroidetes*, which was directly related to the gain in body weight.

Differences in fecal microbiota of infants (6 and 12 months) have been associated with the risk of being overweight or obese at 7 years of age.¹⁶ Children of normal weight had higher *Bifidobacterial* and lower *Staphylococcus aureus* concentrations at ages 6 and 12 months than did children who became overweight/obese.¹⁶ These results suggest that differences in the microbiota precede overweight/obesity.

Although other studies have found changes in gut microbial composition in obese individuals, an increase in the *Firmicutes*:*Bacteroidetes* ratio in obesity and an increased abundance of *Bacteroidetes* during weight loss have not been observed consistently.^{17,18} Confounding factors such as the composition of the diet, energy content of the diet, fasting, and use of antibiotics affect gut microbial composition and may explain the discrepancies between findings in these studies. Future work is needed to determine whether manipulation of the gut microbial community could be an approach for the treatment and/or prevention of obesity.

Call out: Diet can influence the composition of the microbiota

Can diet influence the composition of the gut microbiota?

The composition of the intestinal microbiota is strongly affected by dietary patterns. A high-fat and high-sugar “Western-style” diet increases the relative abundance of *Firmicutes* at the expense of *Bacteroidetes* in animal models.¹⁹ Moreover, switching from a low-fat, plant polysaccharide-rich diet to a high-fat/high sugar “Western” diet may shift the composition of the microbiota within a single day in gnotobiotic mice colonized with bacteria from human feces.²⁰ Similar results have been obtained in humans. In a controlled feeding study, gut microbial changes occurred within 24 hours of initiating a high-fat/low-fiber or a low-fat/high fiber diet.²¹ Moreover, De Filippo et al.²² examined to what extent consumption of a Western diet differentially affects human gut microbial composition as compared with the diets of our ancestors, which was characterized by large amounts of dietary fiber and other plant polysaccharides and lower amounts of fat and animal protein. In this study, the fecal microbiotas of 14 healthy children living in Burkina Faso, Africa, were compared with the fecal microbiotas of 15 healthy children from Florence, Italy. Compared to the feces of children from Italy, the feces of the African children contained higher amounts of *Bacteroidetes* and lower amounts of *Firmicutes*.²²

While mammals have large inter-individual variation in the composition of the gut microbiota, it is unknown whether host genetics or dietary intake is the stronger influence on microbial composition.²³ A very recent study has suggested that diet dominates host genotype in shaping the microbiota of mice. When five inbred and >200 outbred mouse strains were fed a low-fat, high-plant polysaccharide diet or a high-fat, high-sugar diet their microbiota shifted with diet. Consumption of the high-fat, high-sugar diet consistently led to decreased *Bacteroidetes* and increased *Firmicutes* regardless of mouse genotype.²³ These results emphasized the importance of diet on microbiota composition.

Can we prevent obesity by modulation of the gut microbiota?

Targeting microbiota may present new avenues for therapeutic interventions aimed at preventing or treating obesity and associated metabolic disorders. These strategies include dietary manipulation such as the use of prebiotics, probiotics or synbiotics, as well as transplantation of fecal microbial communities.

Prebiotics—A prebiotic is a food ingredient that cannot be digested by the host and whose beneficial effects on the host result from the selective stimulation of growth and/or activity of the gut microbiota, particularly lactobacilli and bifidobacteria.²⁴ Most of the attention in this area has been aimed at nondigestible oligosaccharides.²⁵ Common prebiotics include inulin, other oligosaccharides, lactulose and resistant starch.²⁴ In principle, all dietary fibers that are fermented are assumed to have prebiotic properties.²⁴

Inulin occurs naturally in several foods such as leek, asparagus, chicory, Jerusalem artichoke, garlic, artichoke, onion, wheat, banana, oats and soybeans.²⁵ However, these may not be biologically significant sources because Manning and Gibson²⁶ estimate that an individual would need to consume 4-8 g/day of fructooligosaccharide to significantly (about one log₁₀ value) elevate bifidobacteria in the human gut. A functional food approach has been utilized to add inulin to more frequently consumed products, such as cereals, biscuits, infant foods, yogurts breads and drinks, at concentrations at which a prebiotic effect may occur.²⁵ There are also a number of dietary supplements which contain fructooligosaccharides, primarily inulin, that are commercially available.

Gut hormones such as glucagon-like-peptide-1 (GLP-1) play a critical role in relaying signals of nutritional and energy status from the gut to the central nervous system in order to control food intake. Studies have shown that GLP-1 is upregulated by prebiotics in obese mice suggesting that alterations in intestinal microflora may stimulate or suppress the secretion of gastrointestinal hormones.²⁷ In a double-blind, placebo-controlled study of 16 adults, administration of an inulin-like prebiotic fiber was associated with a significant decrease in hunger, and significantly greater satiation after a meal and increased plasma GLP-1 compared to a similar-tasting placebo (dextrin/maltose).²⁸ These results suggest that prebiotics may be useful for controlling food intake.

In a double-blind, placebo-controlled, cross-over trial, consuming 30 grams isomalt per day (a sugar substitute made from beet sugar) for 4-weeks led to a 65% increase in the proportion of bifidobacteria and a 47% increase in total bifidobacteria cell counts compared to feeding sucrose.²⁹ In another study in which 12 volunteers ingested 10 g inulin/day for 16

days in comparison to a control period without any supplement intake, *Bifidobacterium adolescentis* showed the strongest response, increasing from 0.89 to 3.9% of the total microbiota.³⁰ Therefore, supplementing the diet with prebiotics can alter the gut microbial composition.

Call out: Prebiotics can alter the gut microflora

Probiotics

Probiotics have been defined by the World Health Organization as “live microorganisms which when administered in adequate amounts, confer a health benefit on the host.” Probiotics are usually provided in processed foods or in dietary supplements. Yogurt is the most common probiotic-carrying food; however, cheese, fermented and unfermented milks, juices, smoothies, cereal, nutrition bars, and infant/toddler formula are potential foods that may contain probiotics. In addition, fermented foods such as kim chi, kombucha and raw unfiltered apple cider vinegar, may or may not be considered probiotics depending on the bacteria levels in the food when eaten and whether the bacteria have been shown to confer health benefits.

The main probiotic supplements on the market utilize lactobacilli, streptococci and bifidobacteria, which are normal constituents of the human gastrointestinal microflora. However, studies are also investigating potential probiotic roles of other microbes such as yeast (*Saccharomyces boulardii*), which are not normally found in the gastrointestinal tract.^{31,32} Probiotic microorganisms act in the large intestine by affecting the intestinal flora, but importantly they also affect other organs, either by modulating immunological parameters, intestinal permeability and allowing bacteria to move from the gastrointestinal tract to extraintestinal tissues, or by providing bioactive metabolites.³³

A number of studies with a variety of probiotic strains have been conducted to determine the extent to which probiotics colonize the gastrointestinal tract. These studies have been reviewed by Cothesy et al.³⁴ and reveal that ingested strains do not become established members of the normal microbiota but may persist only during periods of dosing or for relatively short periods afterwards. Undeniably, greater attention is needed about the most beneficial species of probiotics, the optimal number of bacteria that should be provided, the best matrix and exposure duration needed for health promotion.

Evidence from animal studies suggests that the administration of various probiotics (different strains of *Lactobacillus*) may reduce the amount of weight gained in response to a high fat diet and that multi-strain probiotics may prove more beneficial than single-strain probiotics to protect against fat accumulation and metabolic disturbances in diet-induced obesity.³⁵ Similarly, supplementation of *Lactobacillus rhamnosus* NCDC 17, a specific strain of *Lactobacillus*, in fermented milk resulted in a significant decrease in body weight, epididymal fat mass, fasting blood glucose and serum insulin levels in mice fed a high fat diet.³⁶

In addition to bacterial probiotics, other microorganisms such as yeast have also been utilized as probiotics. Interestingly, the probiotic yeast *Saccharomyces boulardii* Biocodex

was shown to improve the metabolic profile of genetically obese and diabetic *db/db* mice.³⁸ Daily consumption of the yeast altered gut microbiota composition, including an increase in *Bacteroidetes* and decrease in *Firmicutes*, with a concurrent decrease in host adiposity and circulating inflammatory markers.

There is also evidence from human studies that probiotics may be beneficial against obesity but the data are less consistent. VSL#3, a commercial multi-species probiotic, was protective against body mass gain and fat accumulation in healthy men (BMI <25) consuming a high-fat (55% fat), hypercaloric diet (+1000 kcal/day) for four weeks compared to placebo.³⁷ A randomized-controlled trial in humans demonstrated that consumption of fermented milk containing the probiotic, *Lactobacillus gasseri* SBT2055 (LG2055) for 12 weeks lead to a significant reduction in abdominal visceral fat area (8.5% decrease, $p < 0.01$) compared to control subjects.³⁹ In a study examining the impact of perinatal probiotic intervention on the development of overweight and obesity in children over 10 years, 159 women were randomized to either *Lactobacillus rhamnosus* or maltodextrin for four weeks before expected delivery and six months postpartum. The authors observed that probiotic treatment may prevent excessive weight gain over the first years of life.⁴⁰ In contrast, other studies have shown no benefit of probiotics for the prevention/ treatment of obesity. One meta-analysis has suggested that probiotics may promote weight loss in adults but weight gain in children.⁴¹ Another meta-analysis demonstrated that the same *Lactobacillus* strain may promote weight gain in undernourished individuals, whereas it may reduce weight gain in obese individuals.⁴² Thus, the effects of probiotics might not only depend on the strain but also on characteristics of the host including age and baseline body weight. More rigorously designed randomized controlled trials are necessary to examine the effect of probiotics on body weight in greater detail.

Synbiotics

The combination of a probiotic with a prebiotic has been termed a “synbiotic”.⁴³ Synbiotics have the potential to induce more substantial effects on the gut microbiota and host health than isolated intake of pre- or probiotics, because they provide the probiotic bacteria in combination with a prebiotic component that stimulates probiotic bacteria survival and growth in the gastrointestinal tract. Evidence suggests that synbiotics may be efficacious in altering the composition of the microbiota. For example, the synbiotic combination of a specific oligofructose-enriched inulin (SYN1) and *Lactobacillus rhamnosus* GG and *Bifidobacterium lactis* Bb12 for 12 weeks caused a 16% and 18% increase in the numbers of *Lactobacillus* and *Bifidobacterium*, respectively, and a 31% decrease in the numbers of *Clostridium perfringens*.⁴⁴ *In vitro* studies have demonstrated that synbiotics were more effective than prebiotics or probiotics in modulating the gut microflora.⁴⁵ These findings need to be documented in well controlled human intervention studies. To date, there have only been a limited number of human studies investigating the potential benefits of synbiotics on obesity.⁴⁶

Fecal Microbial Transplant

Fecal microbial transplants have been found to be an efficacious treatment for patients with *Clostridium difficile* infections but their benefits for other conditions are less well studied.⁴⁷

A randomized controlled trial in obese subjects was conducted to investigate the effects of fecal transplantation on insulin resistance.⁴⁸ Subjects underwent small intestinal biopsies and subsequent bowel lavage through a duodenal tube, followed by random assignment to receive either homogenates of their own feces (autologous) or from healthy, lean donors (allogenic). Results showed a significant improvement in insulin sensitivity (median rate of glucose disappearance after a challenge) in subjects receiving fecal microbiota from lean donors lasting up to six weeks, but no change in those getting their own fecal microbiota.⁴⁸ A trend towards improvement in hepatic insulin sensitivity was also observed. Gut microbial diversity, particularly an increase in butyrate-producing bacteria occurred after allogenic transplants but not after autologous transplants. These experiments suggest that increased bacterial diversity is associated with reduced insulin resistance. However, this was a small study and there was variability in the response—only samples from specific donors had beneficial effects so further studies are needed.

It should be noted that there are dangers associated with fecal microbial transplants since it is not possible to eliminate viral pathogens by filtering and should only be used as a final treatment for human conditions such as recurrent *Clostridium difficile* infection. Moreover, fecal microbial transplants may also have adverse effects on obesity. A recent case report described a patient who underwent a successful fecal microbial transplant for *Clostridium difficile* infection but then developed new-onset obesity after receiving stool from an overweight donor.⁴⁹ These data suggest that the microbial composition can be transmissible and that manipulation of the intestinal microflora may be a potential therapeutic target for the prevention of obesity.

Future Directions

Overall, current evidence supports the potential role of the human gut microbiota in obesity. There are data that suggest that the bacterial composition of gut microbiota differs between obese and lean individuals and that a Western-style diet which is high in fat and refined carbohydrates may promote increased intestinal bacteria linked to obesity. This raises the question whether altering the microbiota can modulate obesity risk or whether knowledge about an individual's microbiota can be used to develop personalized diets for obesity prevention. Perhaps the most exciting data to suggest the importance of the interrelationship between diet and an individual's microbiome comes from a recent study which demonstrated that information about a subject's gut microbiome can be utilized to design personalized diets for glucose homeostasis.⁵⁰ In the study, the authors found that there was large variation in the glycemic response to the same food items between subjects, as well as to the consumption of standardized meals. In an attempt to explain this variation in the glycemic response, the gut microbiome was analyzed with both 16S rDNA and whole metagenomic sequencing and combined with traditional measures, such as blood sugar, diet, physical activity, and body measurements, to create a machine-learning algorithm that accurately predicts personalized responses to real-life meals. Moreover, the algorithm accurately predicted glycemic response in a separate validation cohort and in a follow-up dietary intervention study. This study provides an exciting framework to better understand an individual's response to dietary interventions based on their microbiota. Perhaps the next step would be to use a similar approach to investigate whether information about an

individual's microbiota can predict dietary energy availability and better personalized diets for obesity prevention and/or treatment.

Biography

Cindy Davis, PhD, is Director of Grants and Extramural Activities at the Office of Dietary Supplements, National Institutes of Health. Her PhD is in nutrition. She has more than 125 scientific publications in peer-reviewed journals.

References

1. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature*. 2010; 464:59–65. [PubMed: 20203603]
2. Zoetendal EG, van Wright A, Vilpponen-Salmela T, et al. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from the feces. *Appl. Environ. Microbiol.* 2002; 68:3401–3407. [PubMed: 12089021]
3. Fraher MH, O'Toole PW, Quigley EM. Techniques to characterize the gut microbiota: a guide for the clinician. *Nat. Rev. Gastroenterol. Hepatol.* 2012; 9:312–322.
4. Backhed P, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. *Proc. Natl. Acad. Sci. USA.* 2004; 101:15718–15723. [PubMed: 15505215]
5. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature*. 2006; 444:1027–1031. [PubMed: 17183312]
6. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. *Proc. Natl. Acad. Sci. USA.* 2004; 101:15718–15723. [PubMed: 15505215]
7. Bajzer M, Seeley RJ. Physiology: obesity and gut flora. *Nature*. 2006; 444:1009–1010. [PubMed: 17183300]
8. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance of diet-induced obesity in germ-free mice. *Proc. Natl. Acad. Sci. USA.* 2007; 104:979–984. [PubMed: 17210919]
9. Ley RE, Backhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. *Proc. Natl. Acad. Sci. USA.* 2005; 102:11070–11075. [PubMed: 16033867]
10. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. *Science*. 2013; 34:124124.
11. Wang M, Donovan SM. Human microbiota-associated swine: current progress and future opportunities. *ILAR J.* 2015; 56:63–73. [PubMed: 25991699]
12. Cox LM, Blaser MJ. Antibiotics in early life and obesity. *Nat. Rev. Endocrinol.* 2015; 11:182–190. [PubMed: 25488483]
13. Liou AP, Paziuk M, Luevano JM, et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. *Sci. Transl. Med.* 2013; 5:178ra41.
14. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. *Nature*. 2013; 500:541–546. [PubMed: 23985870]
15. Jumpertz R, Le DS, Turnbaugh PJ, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. *Am. J. Clin. Nutr.* 2011; 94:58–65. [PubMed: 21543530]
16. Kalliomaki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. *Am J Clin Nutr.* 2008; 87:534–538. [PubMed: 18326589]
17. Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. *Proc. Natl. Acad. Sci. USA.* 2009; 108:2365–2370.
18. Duncan SH, Lobleby GE, Holtrop G, et al. Human colonic microbiota associated with diet, obesity and weight loss. *Int. J. Obes.* 2008; 32:1720–1724.

19. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. *Cell Host Microbe*. 2008; 3:213–223. [PubMed: 18407065]
20. Turnbaugh PJ, Ridaura VK, Faith JJ, et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. *Sci. Transl. Med.* 2009; 1:6ra14.
21. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. *Science*. 2011; 334:105–108. [PubMed: 21885731]
22. De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc. Natl. Acad. Sci USA*. 2010; 107:14691–14696. [PubMed: 20679230]
23. Carmody RN, Gerber GK, Luevano JM Jr. et al. Diet dominates host genotype in shaping the murine gut microbiota. *Cell Host Microbe*. 2015; 17:72–84. [PubMed: 25532804]
24. Lim CC, Ferguson LR, Tannock GW. Dietary fibres as “prebiotics”: implications for colorectal cancer. *Mol. Nutr. Food Res*. 2005; 49:609–619. [PubMed: 15864790]
25. Kolinda S, Gibson GR. Prebiotic capacity of inulin-type fructans. *J Nutr*. 2007; 137:2503s–2506s. [PubMed: 17951493]
26. Manning TS, Gibson GR. Microbial-gut interactions in health and disease. *Prebiotics. Best Pract. Res. Clin. Gastroenterol*. 2004; 18:287–298. [PubMed: 15123070]
27. Delzenne NM, Cani PD, Daubioul C, Neyrinck AM. Impact of inulin and oligofructose on gastrointestinal peptides. *Br. J. Nutr*. 2005; 93:S157–S161. [PubMed: 15877889]
28. Cani PD, Lecourt E, Dewulf FM. Gut microbiota fermentation of prebiotics increases satiety and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. *Am. J. Clin. Nutr*. 2009; 90:1236–1243. [PubMed: 19776140]
29. Gostner A, Blaut M, Schaffer V, et al. Effect of isomalt consumption on faecal microflora and colonic metabolism in healthy volunteers. *Br. J. Nutr*. 2006; 95:40–50. [PubMed: 16441915]
30. Ramirez-Farias C, Slezak K, Fuller Z, et al. Effect of inulin on the human gut microbiota: stimulation of *Bifidobacterium adolescentis* and *Faecalibacterium prausnitzii*. *Br. J. Nutr*. 2008; 1:1–10.
31. Penner R, Fedorak RN, Madsen KL. Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. *Curr. Opin. Pharmacol*. 2005; 5:596–603. [PubMed: 16214413]
32. NASPGHAN Nutrition Report Committee. Michail S, Sylvester F, et al. Clinical efficacy of probiotics: review of the evidence with focus on children. *J. Pediatr. Gastroenterol. Nutr*. 2006; 43:550–557. [PubMed: 17033538]
33. de Brese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. *Adv biochem Engin Biotechnol*. 2008; 111:1–66.
34. Corthesy B, Gaskins HR, Mercenier A. Cross-talk between probiotic bacteria and the host immune system. *J. Nutr*. 2007; 137:781s–790s. [PubMed: 17311975]
35. Yoo S-R, Kim Y-J, Park D-Y, et al. Probiotics *L. Plantarum* and *L. Curvatus* in combination alter hepatic lipid metabolism and suppress diet-induced obesity. *Obesity*. 2013; 21:2571–2578. [PubMed: 23512789]
36. Pothuraji R, Sharma RK, Chagalamarri J, et al. Influence of milk fermented with *Lactobacillus rhamnosus* NCD 17 alone and in combination with herbal ingredients on diet induced adiposity and related gene expression in C57BL/6J mice. *Food Func*. 2015; 6:3576–3584.
37. Everard A, Matamoros S, Geurts L, et al. *Saccharomyces boulardii* administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. *MBio*. 2014; 5:e01011–01014. [PubMed: 24917595]
38. Osterberg KL, Boutagy NE, McMillan RP, et al. Probiotic supplementation attenuates increases in body mass and fat mass during high-fat diet in healthy young adults. *Obesity*. 2015; 23:2364–2370. [PubMed: 26466123]
39. Kadooka Y, Sato M, Ogawa A, et al. Effect of *Lactobacillus gasseri* SBT2055 in fermented milk on abdominal adiposity in adults in a randomized controlled trial. *Br. J. Nutr*. 2013; 110:1696–1703. [PubMed: 23614897]

40. Luoto R, Kalliomaki M, Laitinen K, et al. Initial dietary and microbiological environments deviate in normal-weight compared to overweight children at 10 years of age. *J. Pediatr. Gastroenterol. Nutr.* 2011; 52:90–95.
41. Dror T, Dickstein Y, Dubourg G, Paul M. Microbiota manipulation for weight change. *Microbiol. Pathogenesis.* 2016 in press.
42. Million M, Angelakis E, Paul M, et al. Comparative meta-analysis of the effect of *Lactobacillus* species on weight gain in humans and animals. *Microb. Pathog.* 2012; 53:100–108. [PubMed: 22634320]
43. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J. Nutr.* 1995; 125:1401–1412. [PubMed: 7782892]
44. Rafter J, Bennett M, Caderni G, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. *Am. J. Clin. Nutr.* 2007; 85:488–496. [PubMed: 17284748]
45. Saulnier DMA, Gibson GR, Kolida S. *In vitro* effects of selected synbiotics on the human faecal microbiota composition. *FEMS Microbiol Ecol.* 2008:1–12.
46. BEserra BTS, Fernandes R, do Rosario VA, et al. A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentration and lipid parameters in adult patients with overweight and obesity. *Clin. Nutr.* 2015; 34:845–858. [PubMed: 25456608]
47. Schenck LP, Beck PL, MacDonald JA. Gastrointestinal dysbiosis and the use of fecal microbial transplantation in *Clostridium difficile* infection. *World J. Gastrointest. Pathophysiol.* 2015; 6:169–180. [PubMed: 26600975]
48. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology.* 2012; 143:913–916.
49. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. *Open Forum Infect. Dis.* 2015; 2:ofv004. [PubMed: 26034755]
50. Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. *Cell.* 2015; 163:1079–1094. [PubMed: 26590418]
51. Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. *Microbiome.* 2015; 3:31. [PubMed: 26229597]

Table 1A glossary of terms⁵¹

Dysbiosis	A disturbance or imbalance in a biological system. For example, changes in the types and numbers of bacteria in the gut which have been linked to diseases.
Fecal microbial transplant	The introduction of gut bacteria from a healthy donor into a patient via nasogastric tube, nasoduodenal tube or rectal enema
Germ-free	Raised in a sterile environment resulting in no microorganisms living in or on the animal
Gnotobiotic	An animal in which only particular known strains of bacteria and other microorganisms are present. Usually a former germ-free animal that has been colonized with a known microbial community
Lipopolysaccharide (LPS)	A major component of the outer membrane of gram-negative bacteria. A driver of inflammation and associated with the onset of certain diseases
Metagenome	The collection of genomes and genes from the members of a microbiota.
Metagenomics	The process used to characterize the metagenome, from which information on the potential function of the microbiota can be gained.
Metabolomics	The term describes the analytical approaches used to determine the metabolite profile(s) in any given strain or single tissue.
Microbiome	The entire habitat, including the microorganisms (bacteria, archaea, and eukaryotes), their genomes and the surrounding environmental conditions.
Microbiota	The types of organisms that are present in an environment.
Prebiotic	Selectively fermented nondigestible food ingredients that support the growth and/or activity of health-promoting bacteria in the gastrointestinal tract
Probiotic	Live microorganisms that when administered in adequate amounts confers a health benefit on the host.
Shotgun sequencing	An approach used to decode a large strand of DNA by shredding ("shotgunning") it into smaller fragments of DNA which can then be individually sequenced, fragments are overlapped and reassembled
Synbiotic	The combination of a probiotic with a prebiotic to support the viability and activity of the probiotic